These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 22941346

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R, Saito H.
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
    Okamoto I, Nishimura T, Miyazaki M, Yoshioka H, Kubo A, Takeda K, Ebi N, Sugawara S, Katakami N, Fukuoka M, Nakagawa K.
    Clin Cancer Res; 2008 Aug 15; 14(16):5250-4. PubMed ID: 18698044
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
    Yanagimoto H, Satoi S, Sho M, Akahori T, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Kinoshita S, Nishiwada S, Nagai M, Ikeda N, Tsuta K, Nakajima Y, Kon M.
    Cancer Chemother Pharmacol; 2016 Jan 15; 77(1):35-41. PubMed ID: 26645403
    [Abstract] [Full Text] [Related]

  • 8. A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
    Ikemura S, Naoki K, Yasuda H, Kawada I, Yoda S, Terai H, Sato T, Ishioka K, Arai D, Ohgino K, Kamata H, Miyata J, Kabata H, Betsuyaku T, Soejima K.
    Jpn J Clin Oncol; 2015 Apr 15; 45(4):356-61. PubMed ID: 25612761
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH.
    Cancer Chemother Pharmacol; 2013 Nov 15; 72(5):953-64. PubMed ID: 23982118
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.